KR102661616B1 - Gpr156 변이체 및 이들의 용도 - Google Patents

Gpr156 변이체 및 이들의 용도 Download PDF

Info

Publication number
KR102661616B1
KR102661616B1 KR1020197001965A KR20197001965A KR102661616B1 KR 102661616 B1 KR102661616 B1 KR 102661616B1 KR 1020197001965 A KR1020197001965 A KR 1020197001965A KR 20197001965 A KR20197001965 A KR 20197001965A KR 102661616 B1 KR102661616 B1 KR 102661616B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
seq
ser
gpr156
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197001965A
Other languages
English (en)
Korean (ko)
Other versions
KR20190034532A (ko
Inventor
클라우디아 곤자가-하우레기
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020247005755A priority Critical patent/KR20240027874A/ko
Publication of KR20190034532A publication Critical patent/KR20190034532A/ko
Application granted granted Critical
Publication of KR102661616B1 publication Critical patent/KR102661616B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
KR1020197001965A 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도 Active KR102661616B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247005755A KR20240027874A (ko) 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
US62/367,973 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247005755A Division KR20240027874A (ko) 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도

Publications (2)

Publication Number Publication Date
KR20190034532A KR20190034532A (ko) 2019-04-02
KR102661616B1 true KR102661616B1 (ko) 2024-04-30

Family

ID=59649989

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197001965A Active KR102661616B1 (ko) 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도
KR1020247005755A Ceased KR20240027874A (ko) 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247005755A Ceased KR20240027874A (ko) 2016-07-28 2017-07-28 Gpr156 변이체 및 이들의 용도

Country Status (13)

Country Link
US (4) US10266582B2 (enExample)
EP (2) EP4230648A3 (enExample)
JP (2) JP7556688B2 (enExample)
KR (2) KR102661616B1 (enExample)
CN (1) CN109563516B (enExample)
AU (1) AU2017302611B2 (enExample)
CA (1) CA3032124A1 (enExample)
DK (1) DK3491014T5 (enExample)
IL (1) IL264473A (enExample)
MX (2) MX2019001084A (enExample)
NZ (1) NZ751010A (enExample)
SG (1) SG11201900738YA (enExample)
WO (1) WO2018022967A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020150426A1 (en) * 2019-01-17 2020-07-23 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513702A (ja) * 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
EP0879241A4 (en) 1995-11-21 2000-04-19 Icn Pharmaceuticals INHIBITION OF TUMOR GROWTH BY ANTISENSE OLIGONUCLEOTIDES FOR IL-8 AND THE IL-8 RECEPTOR
EP1007655A1 (en) 1996-02-15 2000-06-14 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
AU2001255397A1 (en) * 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
AU2013262709A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
SI3401400T1 (sl) 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
BR112018012744A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método de fabricação de um anel vaginal
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513702A (ja) * 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta (BBA) - Biomembranes 1768(4):976-993(2007.03.28.)

Also Published As

Publication number Publication date
AU2017302611B2 (en) 2021-12-09
IL264473A (en) 2019-02-28
CN109563516B (zh) 2023-10-27
DK3491014T3 (da) 2023-05-30
DK3491014T5 (da) 2024-09-02
US11155598B2 (en) 2021-10-26
NZ751010A (en) 2024-11-29
MX2024013403A (es) 2024-12-06
KR20240027874A (ko) 2024-03-04
EP4230648A2 (en) 2023-08-23
EP4230648A3 (en) 2023-10-18
CA3032124A1 (en) 2018-02-01
CN109563516A (zh) 2019-04-02
US20220073589A1 (en) 2022-03-10
US10562953B2 (en) 2020-02-18
JP2019527229A (ja) 2019-09-26
JP7556688B2 (ja) 2024-09-26
KR20190034532A (ko) 2019-04-02
US20190202891A1 (en) 2019-07-04
JP2023071704A (ja) 2023-05-23
EP3491014B1 (en) 2023-04-05
WO2018022967A1 (en) 2018-02-01
SG11201900738YA (en) 2019-02-27
AU2017302611A1 (en) 2019-03-14
US10266582B2 (en) 2019-04-23
MX2019001084A (es) 2019-06-10
EP3491014A1 (en) 2019-06-05
US20200231651A1 (en) 2020-07-23
US20180030114A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
CN113853437A (zh) 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
KR20180093902A (ko) 태아와 임신 여성간에 상이하게 메틸화된 디엔에이 영역을 이용한 태아 염색체 이수성의 검출
KR102661616B1 (ko) Gpr156 변이체 및 이들의 용도
KR102493894B1 (ko) 인간화 tmprss 유전자를 갖는 설치류
KR20120099363A (ko) 탯줄 혈액으로부터의 유도 만능 줄기 세포의 생성
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
US20080199480A1 (en) Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
CN1704478A (zh) 评估急性髓性白血病患者的方法
KR20210116480A (ko) 기분 장애의 설치류 모델
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US20040171003A1 (en) Cancer-associated genes
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022633A1 (en) Methods for identifying a risk of type ii diabetes and treatments thereof
CN1795379A (zh) 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
JP2003259875A (ja) ヒト遺伝子の一塩基多型（４）
TW202313972A (zh) 新ｎｒｇ１融合物、融合接合處及檢測彼等之方法
CN114053413A (zh) 一种col4a4基因作为急性缺血性卒中治疗靶点的应用
JP2003180359A (ja) 新規遺伝子及びそれにコードされる蛋白質
JP2003116575A (ja) 新規遺伝子及びそれにコードされる蛋白質

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200724

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220830

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230528

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230528

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20220830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240220

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230818

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20221223

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200724

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240226

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240220

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20231030

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230818

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20221223

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200724

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240424

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240425

End annual number: 3

Start annual number: 1

PG1601 Publication of registration